Evidence map›Paper›PMID 30567994›Full record

ArticleJournal of virology2019

Evolution of the Envelope Glycoprotein of HIV-1 Clade B toward Higher Infectious Properties over the Course of the Epidemic.

Mélanie Bouvin-Pley, Maxime Beretta, Alain Moreau, Emmanuelle Roch, Asma Essat, Cécile Goujard, Marie-Laure Chaix, Nathalie Moiré, Loïc Martin, Laurence Meyer and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Mélanie Bouvin-PleyUniversité de Tours, Inserm U1259, Tours, France.
Maxime BerettaUniversité de Tours, Inserm U1259, Tours, France.
Alain MoreauUniversité de Tours, Inserm U1259, Tours, France.
Emmanuelle RochUniversité de Tours, Inserm U1259, Tours, France.
Asma EssatUniversité Paris Sud, Université Paris Saclay, CESP Inserm U1018, Le Kremlin-Bicêtre, France.
Cécile GoujardUniversité Paris Sud, Université Paris Saclay, CESP Inserm U1018, Le Kremlin-Bicêtre, France.
Marie-Laure ChaixUniversité Paris Diderot, Inserm U941, Paris, France.
Nathalie MoiréUniversité de Tours et INRA, UMR1282, Tours, France.
Loïc MartinCommissariat à l'énergie atomique, Institut de biologie et de technologies de Saclay, Gif-sur-Yvette, France.
Laurence Meyer *Université Paris Sud, Université Paris Saclay, CESP Inserm U1018, Le Kremlin-Bicêtre, France.
Francis Barin *Université de Tours, Inserm U1259, Tours, France.
Martine BraibantUniversité de Tours, Inserm U1259, Tours, France braibant@med.univ-tours.fr.
Université de Tours · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Tours · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRHôpital Saint-Louis · FRInserm · FRUniversité Paris-Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We showed previously that during the HIV/AIDS epidemic, the envelope glycoprotein (Env) of HIV-1, and in particular, the gp120 subunit, evolved toward an increased resistance to neutralizing antibodies at a population level. Here, we considered whether the antigenic evolution of the HIV-1 Env is associated with modifications of its functional properties, focusing on cell entry efficacy and interactions with the receptor and coreceptors. We tested the infectivity of a panel of Env-pseudotyped viruses derived from patients infected by subtype B viruses at three periods of the epidemic (1987 to 1991, 1996 to 2000, and 2006 to 2010). Pseudotyped viruses harboring Env from patients infected during the most recent period were approximately 10-fold more infectious in cell culture than those from patients infected at the beginning of the epidemic. This was associated with faster viral entry kinetics: contemporary viruses entered target cells approximately twice as fast as historical viruses. Contemporary viruses were also twice as resistant as historical viruses to the fusion inhibitor enfuvirtide. Resistance to enfuvirtide correlated with a resistance to CCR5 antagonists, suggesting that contemporary viruses expanded their CCR5 usage efficiency. Viruses were equally captured by DC-SIGN, but after binding to DC-SIGN, contemporary viruses infected target cells more efficiently than historical viruses. Thus, we report evidence that the infectious properties of the envelope glycoprotein of HIV-1 increased during the course of the epidemic. It is plausible that these changes affected viral fitness during the transmission process and might have contributed to an increasing virulence of HIV-1.

Indexed as

Antibodies, NeutralizingCell Lineenv Gene Products, Human Immunodeficiency VirusEpidemicsHEK293 CellsHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHumansMaleNeutralization TestsReceptors, CCR5Virus InternalizationAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesHIV Envelope Protein gp120Receptors, CCR5envelopeevolutionhuman immunodeficiency virusinfectivity

Identifiers

PMID30567994
PMCPMC6401426
OpenAlexW2903694818

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.